BURN 60mg
- Retatrutide20 mg
- Tirzepatide40 mg
Curated multi-peptide research blend of lyophilized reference materials supplied with batch-specific Certificate of Analysis. For in-vitro laboratory research use only. Not for human or veterinary use.
Sold strictly as a lyophilized analytical reference standard for in-vitro laboratory research by qualified professionals. Not for use in any living organism. Not a drug, food, cosmetic, or dietary supplement. No medical, therapeutic, diagnostic, or health claims are made. No dosing or administration guidance is provided.
Research Overview
A dual metabolic blend — Retatrutide 20 mg paired with Tirzepatide 40 mg in one 60 mg vial.
BURN combines two of the most-studied incretin peptides in current metabolic literature. Retatrutide engages the GLP-1, GIP, and glucagon receptors, while Tirzepatide acts as a dual GLP-1 / GIP agonist. Researchers use combined preparations like this to study overlapping receptor pathways in a single reference material. Published work is early-stage and reflects only what was measured under those study conditions.
- Overlapping GLP-1, GIP, and glucagon receptor activity
- Appetite and satiety signaling pathways
- Glucose handling in research models
- Energy use and substrate metabolism markers
For laboratory reference information only. Not for human or animal use. No preparation or administration guidance is provided.
Certificate of Analysis
No matching report is currently published for this exact product and strength. Contact support with the lot printed on your vial to request available documentation.
- Compound
- BURN 60mg
- CAS
- N/A
- Method
- See the exact report methods
- Purity
- >99.0% (HPLC)
- Grade
- Research
- Net Content
- 60 mg / vial